Compugen Ltd. - Ordinary Shares (CGEN): Price and Financial Metrics


Compugen Ltd. - Ordinary Shares (CGEN)

Today's Latest Price: $12.56 USD

0.32 (-2.48%)

Updated Dec 2 4:00pm

Add CGEN to Watchlist
Sign Up

Overall POWR Rating

Sign Up to See Ratings...FREE!

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 389 in Biotech

See all "A" rated Strong Buy stocks

CGEN Stock Price Chart Interactive Chart >

Price chart for CGEN

CGEN Price/Volume Stats

Current price $12.56 52-week high $19.90
Prev. close $12.88 52-week low $5.20
Day low $12.30 Volume 912,741
Day high $12.80 Avg. volume 1,225,180
50-day MA $14.48 Dividend yield N/A
200-day MA $13.87 Market Cap 859.36M

Compugen Ltd. - Ordinary Shares (CGEN) Company Bio

Compugen Ltd. engages in the research, development, and commercialization of therapeutic and product candidates primarily in the United States, Europe, and Israel. The company was founded in 1993 and is headquartered in Tel Aviv, Israel.

Most Popular Stories View All

• Are Stocks Off to the Races in December?

• 3 Top Growth Stocks to Buy and Hold for Long Term

• Swerve to Avoid these 2 Electric Vehicle Stocks in December!

• 3 Top Airline Stocks to Buy for a Post Pandemic-World

• 4 Dividend-Paying Tech Stocks to Buy Before the New Year

View All Top Stories

CGEN Latest News Stream

Event/Time News Detail
Loading, please wait...
View All CGEN News

CGEN Latest Social Stream

Loading social stream, please wait...

View Full CGEN Social Stream

Latest CGEN News From Around the Web

Below are the latest news stories about Compugen Ltd that investors may wish to consider to help them evaluate CGEN as an investment opportunity.

Compugen launches early-stage combination study for COM701 in solid tumors

Dosing is underway in Compugen's ([[CGEN]] -3.1%) Phase 1/2 study evaluating the triple combination of Compugen's COM701, with Bristol Myers Squibb's Opdivo (nivolumab), and their investigational anti-TIGIT antibody, BMS-986207, for solid tumors.The 100-subject trial is designed to evaluate the safety, tolerability and preliminary antitumor activity of COM701+Opdivo+BMS 986207 combo during dose...

Seeking Alpha | September 8, 2020

Evogene: Hidden Gems Of Computational Predictive Biology, Part 1 Of 4 (Biomica, Microbiome Therapeutics)

Based in Israel, Evogene Ltd. (EVGN) has developed a unique computational predictive biology "CPB" platform, which leverages big data with advanced algorithms such as machine learning and other artificial intelligence ("AI"), while adding a deep understanding of biology and advanced biological technologies. Evogene is using its proprietary CPB platform to...

Steven Goldman on Seeking Alpha | August 14, 2020

Compugen Ltd. (CGEN) Q2 2020 Earnings Call Transcript

CGEN earnings call for the period ending June 30, 2020.

Yahoo | July 31, 2020

Compugen Reports Second Quarter 2020 Results

Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today reported financial results for the second quarter ended June 30, 2020.

Yahoo | July 30, 2020

Compugen to Release Second Quarter 2020 Results on Thursday, July 30, 2020

Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced today that the Company will release its second quarter 2020 financial results on Thursday, July 30, 2020 before the U.S. financial markets open. Management will host a conference call and webcast to review the results and provide a corporate update at 8:30 AM ET.

Yahoo | July 16, 2020

Read More 'CGEN' Stories Here

CGEN Price Returns

1-mo -1.34%
3-mo -21.60%
6-mo -7.71%
1-year 134.77%
3-year 412.65%
5-year 69.27%
YTD 110.74%
2019 174.65%
2018 -13.20%
2017 -50.98%
2016 -20.19%
2015 -23.29%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.7467 seconds.